[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441423":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":7,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":28,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":35,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Mirdametinib (MEK Inhibitor)","Patients will receive oral mirdametinib.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"US Medical Information","CONTACT","888-275-7376","eMediUSA@emdserono.com",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100441423","individual-patient-compassionate-use-of-mirdametinib-100441423",false,"NCT05028166","Individual Patient Compassionate Use of Mirdametinib","Inclusion Criteria:\n\n* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.\n* Patient does not qualify to participate in an ongoing clinical trial.","ALL","2 Years","EXPANDED_ACCESS","This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee, and applicable competent authority approval.",[32,33,34],"Neurofibromatosis Type 1-Associated Plexiform Neurofibromas","Histiocytic Neoplasm","Other MAP-K Pathway Driven Diseases",[36,37,38,39,40],"RASopathies","NF1","Neurofibromatosis","Plexiform Neurofibromas","Langerhans","AVAILABLE","2026-05-04",{"date":44,"type":45},"2026-05-08","ACTUAL",{"name":47,"class":6},"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany"]